Thomson Reuters Corp (TRI) Stock Price Today
Key Stats
- $44.45BMarket Cap
- -Volume
- IndustrialsSector
- $178.7752W High
- $76.5552W Low
- -Typical Hold Time
- $47.07BEnterprise Value
- 2.55%Div Yield
- -Trading Activity
Track Thomson Reuters Corp (TRI) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Thomson Reuters Corp has traded between a low of $76.55 and a high of $178.77, highlighting its annual price range. Buy and sell Thomson Reuters Corp shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Most Recent News
Stocks fall sharply amid fraud probe and mixed earnings, with Cellebrite down 29%.
Several stocks dropped significantly today due to various company-specific issues. Cellebrite DI Ltd. plunged 29.18% following a securities fraud investigation, while Securitize Corp. fell 27.48% despite a major NYSE listing milestone. Liftoff Mobile...

Altimmune CEO buys shares, signaling confidence amid strong Q2 results and MASH drug progress.
Altimmune's CEO recently purchased 15,000 shares at $2.95 each, showing strong leadership confidence in the company's future. The biopharmaceutical firm reported a better-than-expected Q2 loss of $0.12 per share and holds $519 million in cash, securi...

Medline stock drops over 7% after FDA cites major manufacturing violations
Medline Inc. faced significant FDA violations related to manufacturing quality, including failure to investigate contamination and cleaning issues. The FDA issued a warning letter in May 2026, marking the second such action in two months. Following t...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.